Clostridioides difficile (C. difficile) by Centers for Disease Control and Prevention (U.S.) & National Center for Emerging Zoonotic and Infectious Diseases (U.S.). Division of Healthcare Quality Promotion. Antibiotic Resistance Coordination and Strategy Unit .
CLOSTRIDIOIDES DIFFICILE 
THREAT LEVEL URGENT
223,900
Estimated cases 
in hospitalized 
patients in 2017 
12,800
Estimated 
deaths in 2017 
$1B
Estimated attributable 
healthcare costs in 2017
Clostridioides difficile (C. difficile) bacteria can cause life-threatening diarrhea. Infections occur most often in 
people who have taken antibiotics for other conditions. It is the most common healthcare-associated infection. 
WHAT YOU NEED TO KNOW
 ■ While healthcare-associated C. difficile cases are 
decreasing, community-associated cases are not. 
 ■ Strategies to reduce C. difficile infections include 
improving antibiotic use, infection control, and 
healthcare facility cleaning and disinfection.
 ■ C. difficile infections are more common and tend to 
be more severe in older patients.
Previously Clostridium difficile. Also called C. diff. Cost includes hospital-
onset cases only.
CASES OVER TIME
Continued appropriate infection control, antibiotic use, and 
diagnostic testing are important to maintain decreases in  
C. difficile cases. 
CLOSTRIDIOIDES DIFFICILE 
WHERE INFECTIONS HAPPEN 
C. difficile infection affects thousands of people every 
year. It is rarely resistant to antibiotics; however,  
C. difficile usually occurs in people who have taken 
antibiotics. Improving antibiotic use is an important 
strategy to reduce these infections. Antibiotics disrupt 
(unbalance) our microbiome (a community of germs). 
A common strain of C. difficile (ribotype 027) that can 
cause more serious disease can be associated with use 
of certain antibiotics, such as fluoroquinolones. 
More than half of C. difficile cases among long-term 
care facility residents happen in those who were 
recently hospitalized. However, from 2011 to 2015, 
sites within CDC’s Emerging Infections Program saw 
a decrease in C. difficile cases in people 65 years or 
older in long-term care facilities. During this same 
time, there were declines in hospital fluoroquinolone 
antibiotic use and C. difficile ribotype 027 among 
people 65 years or older. Improving antibiotic use may 
have contributed to the decrease in C. difficile cases. 
C. DIFFICILE CASES
Improving antibiotic use may have contributed to the decrease 
in long-term care facility-onset C. difficile cases in 10 U.S. sites.
Adjusted cases for sex, race, and the percent of cases diagnosed by nucleic 
acid amplification test. 
ONLINE RESOURCES
About C. difficile Infections
www.cdc.gov/cdiff/index.html
Tracking C. difficile Infections 
www.cdc.gov/hai/eip/cdiff-tracking.html   
This fact sheet is part of CDC’s 2019 Antibiotic Resistance Threats Report.  
The full report, including data sources, is available at www.cdc.gov/DrugResistance/Biggest-Threats.html.
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